UA111415C2 - Pharmaceutical preparation containing dihydroquinazoline derivative possessing antiviral activity - Google Patents
Pharmaceutical preparation containing dihydroquinazoline derivative possessing antiviral activityInfo
- Publication number
- UA111415C2 UA111415C2 UAA201410519A UAA201410519A UA111415C2 UA 111415 C2 UA111415 C2 UA 111415C2 UA A201410519 A UAA201410519 A UA A201410519A UA A201410519 A UAA201410519 A UA A201410519A UA 111415 C2 UA111415 C2 UA 111415C2
- Authority
- UA
- Ukraine
- Prior art keywords
- pharmaceutical preparation
- preparation containing
- antiviral activity
- derivative possessing
- possessing antiviral
- Prior art date
Links
- NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical class C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 title 1
- 230000000840 anti-viral effect Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- FWYSMLBETOMXAG-UHFFFAOYSA-N 2-[8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetic acid Chemical compound COC1=CC=CC(N2CCN(CC2)C=2N(C(CC(O)=O)C3=CC=CC(F)=C3N=2)C=2C(=CC=C(C=2)C(F)(F)F)OC)=C1 FWYSMLBETOMXAG-UHFFFAOYSA-N 0.000 abstract 1
- 239000004475 Arginine Substances 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- 241000701022 Cytomegalovirus Species 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
У заявці описано фармацевтичні препарати, насамперед призначені для внутрішньовенного введення, які містять {8-фтор-2-[4-(3-метоксифеніл)піперазин-1-іл]-3-[2-метокси-5-(трифторметил)феніл]-3,4-дигідрохіназолін-4-іл}оцтову кислоту в комбінації принаймні з однією допоміжною речовиною, вибраною з циклодекстринів, лізину і аргініну, способи їх одержання, а також їх застосування для лікування та/або профілактики захворювань, передусім їх застосування як противірусних засобів, насамперед проти цитомегаловірусів.The application discloses pharmaceuticals primarily intended for intravenous administration containing {8-fluoro-2- [4- (3-methoxyphenyl) piperazin-1-yl] -3- [2-methoxy-5- (trifluoromethyl) phenyl] -3,4-dihydroquinazolin-4-yl} acetic acid in combination with at least one excipient selected from cyclodextrins, lysine and arginine, methods for their preparation, and their use for the treatment and / or prevention of diseases, especially their use as antiviral drugs, especially against cytomegaloviruses.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102012101680A DE102012101680A1 (en) | 2012-02-29 | 2012-02-29 | Pharmaceutical preparation containing an antiviral dihydroquinazoline derivative |
| PCT/EP2013/054114 WO2013127970A1 (en) | 2012-02-29 | 2013-02-28 | Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA111415C2 true UA111415C2 (en) | 2016-04-25 |
Family
ID=47757622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201410519A UA111415C2 (en) | 2012-02-29 | 2013-02-28 | Pharmaceutical preparation containing dihydroquinazoline derivative possessing antiviral activity |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US10603384B2 (en) |
| EP (3) | EP3556350B1 (en) |
| JP (1) | JP6387486B2 (en) |
| KR (1) | KR102149561B1 (en) |
| CN (2) | CN104144678A (en) |
| AU (1) | AU2013224947B2 (en) |
| BR (1) | BR112014020946B1 (en) |
| CA (1) | CA2865203C (en) |
| CL (1) | CL2014002306A1 (en) |
| CO (1) | CO7061076A2 (en) |
| CY (1) | CY1121910T1 (en) |
| DE (1) | DE102012101680A1 (en) |
| DK (2) | DK2819648T3 (en) |
| EA (1) | EA026584B1 (en) |
| ES (2) | ES2741698T3 (en) |
| FI (1) | FI3556350T3 (en) |
| HR (2) | HRP20240197T1 (en) |
| HU (2) | HUE065553T2 (en) |
| IL (1) | IL234363B (en) |
| IN (1) | IN2014MN01892A (en) |
| LT (2) | LT3556350T (en) |
| MA (1) | MA35941B1 (en) |
| ME (1) | ME03448B (en) |
| MX (1) | MX369666B (en) |
| MY (1) | MY172310A (en) |
| NZ (1) | NZ628444A (en) |
| PH (1) | PH12014501937B1 (en) |
| PL (2) | PL2819648T3 (en) |
| PT (2) | PT2819648T (en) |
| RS (2) | RS59157B1 (en) |
| SG (1) | SG11201405294XA (en) |
| SI (2) | SI2819648T1 (en) |
| SM (2) | SMT201900458T1 (en) |
| TN (1) | TN2014000345A1 (en) |
| UA (1) | UA111415C2 (en) |
| WO (1) | WO2013127970A1 (en) |
| ZA (1) | ZA201405949B (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (en) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituted dihydroquinazolines |
| SMT201900327T1 (en) * | 2013-06-19 | 2019-07-11 | Aicuris Anti Infective Cures Gmbh | Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration |
| EP3463064B1 (en) | 2016-06-03 | 2021-11-03 | Atreya Innovations Private Limited | A device for the detection and reliable capturing of the pulse characteristics |
| SG11201908181XA (en) | 2017-03-06 | 2019-10-30 | Venatorx Pharmaceuticals Inc | Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof |
| UY39099A (en) * | 2020-02-27 | 2021-08-31 | Aic246 Gmbh & Co Kg | 2 - [(4S) -8-FLUORO-2- [4- (3-METOXIFENIL) PIPERAZIN-1-IL] -3- [2-METOXI-5- (TRIFLUOROMETIL) FENIL] -4H-QUINAZOLIN-4-IL ] SODIUM ACETATE AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| AR121438A1 (en) * | 2020-02-27 | 2022-06-08 | Aic246 Gmbh & Co Kg | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-[(4S)-8-FLUORO-2-[4-(3-METHOXYPHENYL)PIPERAZIN-1-IL]-3-[2-METHOXY-5-(TRIFLUOROMETHYL)PHENYL]-4H ACETATE -QUINAZOLIN-4-IL] AND SODIUM IONS |
| CN114539085B (en) * | 2020-11-26 | 2023-10-20 | 山东诚创蓝海医药科技有限公司 | Preparation of ureido derivatives |
| CN115403528B (en) * | 2021-05-27 | 2025-01-07 | 南京正大天晴制药有限公司 | Preparation method of amorphous 3,4-dihydroquinazoline derivatives |
| CN113880776B (en) * | 2021-11-16 | 2023-06-16 | 山东诚创蓝海医药科技有限公司 | Preparation method of rituximab intermediate |
| UY40078A (en) * | 2021-12-21 | 2023-06-30 | Aic246 Ag & Co Kg | PHARMACEUTICAL COMPOSITIONS COMPRISING 2-[(4S)-8-FLUORO-2-[4-(3-METHOXYPHENYL)PIPERAZIN ACETATE] |
| WO2023163470A1 (en) * | 2022-02-23 | 2023-08-31 | 주식회사 엘지화학 | Injectable formulation comprising isoxazoline derivative and method for preparing same |
| CN115322157B (en) * | 2022-06-02 | 2023-12-05 | 浙江车头制药股份有限公司 | Letermopevir intermediate compound, preparation method and application thereof |
| WO2024037485A1 (en) * | 2022-08-15 | 2024-02-22 | 上海迪赛诺化学制药有限公司 | Preparation method for letermovir amorphous form |
| CN115677539B (en) * | 2022-11-01 | 2023-10-24 | 南京工业大学 | A cobalt-catalyzed method for highly selective monoalkenylation of urea-directed aromatics under mild conditions |
| CN119015222B (en) * | 2024-08-28 | 2025-12-09 | 石家庄四药有限公司 | Leitemivir injection and preparation method thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1242699A (en) * | 1985-02-01 | 1988-10-04 | Bristol-Myers Company | Cefbuperazone and derivatives thereof |
| FR2585705B1 (en) * | 1985-08-05 | 1989-01-13 | Bristol Myers Co | CEPHALOSPORIN SALTS AND INJECTABLE COMPOSITIONS |
| JP3552240B2 (en) * | 1993-02-23 | 2004-08-11 | 第一製薬株式会社 | High concentration TCF preparation |
| JPH11209277A (en) * | 1998-01-19 | 1999-08-03 | Yoshitomi Pharmaceut Ind Ltd | Pharmaceutical composition |
| IT1304190B1 (en) * | 1998-12-18 | 2001-03-08 | Euphar Group Srl | DEHYDROEPIANDROSTERONE CLATRATES AND RELATED PHARMACEUTICAL COMPOSITIONS |
| BR0009083B1 (en) * | 1999-03-17 | 2011-11-01 | an amide derivative comprising a quinazolinone nucleus, process for the preparation of an amide derivative, pharmaceutical composition, and use of an amide derivative. | |
| WO2001091751A1 (en) * | 2000-05-30 | 2001-12-06 | Novo Nordisk A/S | New pharmaceutical composition and the process for its preparation |
| DE10319612A1 (en) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituted dihydroquinazolines |
| KR20060127413A (en) * | 2003-11-25 | 2006-12-12 | 카이론 코포레이션 | Quinazolinone Compounds as Anticancer Agents |
| ATE421518T1 (en) | 2005-02-10 | 2009-02-15 | Bristol Myers Squibb Co | DIHYDROQUINAZOLINONES AS 5HT MODULATORS |
| DE102005027517A1 (en) | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Process for the preparation of dihydroquinazolines |
| US8743287B2 (en) * | 2009-07-24 | 2014-06-03 | Broadcom Corporation | Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction |
-
2012
- 2012-02-29 DE DE102012101680A patent/DE102012101680A1/en not_active Ceased
-
2013
- 2013-02-28 RS RSP20191076 patent/RS59157B1/en unknown
- 2013-02-28 RS RS20240135A patent/RS65137B1/en unknown
- 2013-02-28 PL PL13707000T patent/PL2819648T3/en unknown
- 2013-02-28 ES ES13707000T patent/ES2741698T3/en active Active
- 2013-02-28 PT PT13707000T patent/PT2819648T/en unknown
- 2013-02-28 WO PCT/EP2013/054114 patent/WO2013127970A1/en not_active Ceased
- 2013-02-28 EP EP19176985.0A patent/EP3556350B1/en active Active
- 2013-02-28 SI SI201331541T patent/SI2819648T1/en unknown
- 2013-02-28 PH PH1/2014/501937A patent/PH12014501937B1/en unknown
- 2013-02-28 UA UAA201410519A patent/UA111415C2/en unknown
- 2013-02-28 ME MEP-2019-219A patent/ME03448B/en unknown
- 2013-02-28 HR HRP20240197TT patent/HRP20240197T1/en unknown
- 2013-02-28 EA EA201400963A patent/EA026584B1/en unknown
- 2013-02-28 JP JP2014559233A patent/JP6387486B2/en active Active
- 2013-02-28 SM SM20190458T patent/SMT201900458T1/en unknown
- 2013-02-28 MX MX2014010364A patent/MX369666B/en active IP Right Grant
- 2013-02-28 ES ES19176985T patent/ES2972133T3/en active Active
- 2013-02-28 SI SI201332077T patent/SI3556350T1/en unknown
- 2013-02-28 CN CN201380011670.7A patent/CN104144678A/en active Pending
- 2013-02-28 DK DK13707000.9T patent/DK2819648T3/en active
- 2013-02-28 BR BR112014020946-4A patent/BR112014020946B1/en active IP Right Grant
- 2013-02-28 CA CA2865203A patent/CA2865203C/en active Active
- 2013-02-28 LT LTEP19176985.0T patent/LT3556350T/en unknown
- 2013-02-28 PT PT191769850T patent/PT3556350T/en unknown
- 2013-02-28 DK DK19176985.0T patent/DK3556350T3/en active
- 2013-02-28 CN CN201910661203.8A patent/CN110433166A/en active Pending
- 2013-02-28 MY MYPI2014002461A patent/MY172310A/en unknown
- 2013-02-28 HU HUE19176985A patent/HUE065553T2/en unknown
- 2013-02-28 NZ NZ628444A patent/NZ628444A/en unknown
- 2013-02-28 EP EP13707000.9A patent/EP2819648B1/en active Active
- 2013-02-28 AU AU2013224947A patent/AU2013224947B2/en active Active
- 2013-02-28 IN IN1892MUN2014 patent/IN2014MN01892A/en unknown
- 2013-02-28 HU HUE13707000A patent/HUE045949T2/en unknown
- 2013-02-28 SG SG11201405294XA patent/SG11201405294XA/en unknown
- 2013-02-28 US US14/381,290 patent/US10603384B2/en active Active
- 2013-02-28 KR KR1020147023803A patent/KR102149561B1/en active Active
- 2013-02-28 SM SM20240068T patent/SMT202400068T1/en unknown
- 2013-02-28 PL PL19176985.0T patent/PL3556350T3/en unknown
- 2013-02-28 HR HRP20191369 patent/HRP20191369T1/en unknown
- 2013-02-28 EP EP24150976.9A patent/EP4328218A3/en active Pending
- 2013-02-28 LT LTEP13707000.9T patent/LT2819648T/en unknown
- 2013-02-28 FI FIEP19176985.0T patent/FI3556350T3/en active
-
2014
- 2014-08-08 TN TNP2014000345A patent/TN2014000345A1/en unknown
- 2014-08-13 ZA ZA2014/05949A patent/ZA201405949B/en unknown
- 2014-08-28 CO CO14189543A patent/CO7061076A2/en unknown
- 2014-08-28 IL IL234363A patent/IL234363B/en active IP Right Grant
- 2014-08-29 CL CL2014002306A patent/CL2014002306A1/en unknown
- 2014-09-17 MA MA37360A patent/MA35941B1/en unknown
-
2019
- 2019-08-20 CY CY20191100885T patent/CY1121910T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA111415C2 (en) | Pharmaceutical preparation containing dihydroquinazoline derivative possessing antiviral activity | |
| CY1120832T1 (en) | NUCLEAR TRANSPORT MODIFIERS AND THEIR USES | |
| BR112014032699A2 (en) | Pediatric metabolic syndrome treatment methods | |
| HUE061596T2 (en) | Substituted dimer quinazoline derivative, its preparation and application in I. and II. in medicinal products for the treatment of type 2 diabetes | |
| WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
| BR112013030894A2 (en) | immune system modulators | |
| JO3122B1 (en) | Derivatives of Astra-1,3,5 (10), 16-Tetraine-3-carboxamide, preparations, pharmaceutical preparations, and use for the preparation of drugs | |
| MX378183B (en) | COMPOSITIONS OF HIGH PENETRATION PRODRUGS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF LUNG CONDITIONS. | |
| EA032938B1 (en) | Glutarimide derivative, use thereof, pharmaceutical composition based thereon, process for preparing same | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| GEP20156332B (en) | Pyrazoles as crth2 antagonists | |
| EA201590415A1 (en) | DERIVATIVES OF DIAZEPINONA APPLICABLE FOR THE TREATMENT OF SYNDROME WITH Fragile X-CHROMOSOME, PARKINSON'S DISEASE OR REFLUX DISEASE | |
| BR112013026352A2 (en) | solid pharmaceutical composition | |
| WO2012145234A3 (en) | Cyclopropyl derivatives and methods of use | |
| EA201892350A1 (en) | PREPARATION FOR INHALATION ON THE BASIS OF ISOGLYCYRRISINIC ACID OR ITS SALT AND ITS APPLICATION IN THE OBTAINING OF MEDICINES FOR TREATING DISEASES OF THE RESPIRATORY SYSTEM | |
| EA201200271A1 (en) | SOLID MEDICAL FORM, OWNED BY NEUROPROTECTIVE, ANTI-AMNESTIC, ANTIOXIDANT, ANTIPOGOPSIC, ANTIHYCHEMICAL ACTIVITY (OPTIONS) | |
| Colquhoun | Response to Whitehead | |
| TH158863A (en) | Pharmaceutical components containing dihydroquinasoline derivatives that have antiviral effects. | |
| TH160505A (en) | Compounds and methods for enhancing the innate immune response | |
| TH152461A (en) | 3-pyrimidin-4-il-oxasolidin-2-transfer as a inhibitor of mutated IDH. | |
| TH152460A (en) | Inhibitors of new virus proliferation | |
| TH112398A (en) | Pharmaceutical constituents for Parkinson's disease | |
| PL399880A1 (en) | 8- (octadecylsulfanyl) quinoline for use as a medicine, especially for use in the treatment and prophylaxis of insulin resistance development, a pharmaceutical composition containing 8- (octadecylsulfanyl) quinoline and the use of 8- (octadecylsulfanyl) quinoline for the preparation of a medicament for use in the treatment and prophylaxis of insulinopathy | |
| TH147124A (en) | Long-acting insulin formulation | |
| EA201101486A1 (en) | METHOD FOR OBTAINING A MEDICINE FOR PREVENTION AND TREATMENT OF INFLUENZA AND COMPOSITIONS FOR ITS USE |